Published in Am J Med on April 01, 1983
Carumonam (Ro 17-2301; AMA-1080) compared with gentamicin for treatment of complicated urinary tract infections. Antimicrob Agents Chemother (1988) 0.85
A prospective randomized trial of imipenem-cilastatin versus clindamycin/tobramycin in the treatment of intra-abdominal and pelvic infections. Can J Infect Dis (1993) 0.75
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 13.84
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 8.52
The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res (1999) 3.36
Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med (1981) 3.19
A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N Engl J Med (1993) 2.98
Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol (1997) 2.75
Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. J Clin Invest (1988) 2.54
Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med (1980) 2.51
Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy. Lancet (1982) 2.28
Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res (2001) 2.27
Redefined nomenclature for members of the carcinoembryonic antigen family. Exp Cell Res (1999) 2.25
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol (2001) 2.24
Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside. Lancet (1978) 2.10
Mycophenolate mofetil for Crohn's disease? Lancet (1999) 2.03
Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med (1983) 1.90
Therapy of herpes zoster with oral acyclovir. Am J Med (1988) 1.89
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology (1999) 1.84
Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther (1987) 1.84
Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA (1989) 1.84
Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments]. Ann Surg Oncol (1998) 1.78
Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol (2001) 1.69
The need for standardized pathologic staging of pancreaticoduodenectomy specimens. Pancreas (1996) 1.68
Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res (1999) 1.60
A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol (2000) 1.58
Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med (1984) 1.57
Herpes zoster and zosteriform herpes simplex virus infections in immunocompetent adults. Am J Med (1986) 1.50
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res (2000) 1.47
Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res (2001) 1.46
Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J Gastroenterol (2000) 1.46
Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res (1999) 1.45
A randomized trial of prostaglandin E2 in a controlled-release vaginal pessary for cervical ripening at term. Am J Obstet Gynecol (1992) 1.44
Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene (2001) 1.41
N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia. Lancet (1983) 1.41
The functional interactions between CD98, beta1-integrins, and CD147 in the induction of U937 homotypic aggregation. Blood (2001) 1.39
Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation. Int J Radiat Oncol Biol Phys (1995) 1.39
Methylphenidate: its pharmacology and uses. Mayo Clin Proc (2000) 1.39
Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem (1999) 1.38
Use of ganciclovir to treat serious cytomegalovirus infections in patients with AIDS. J Infect Dis (1987) 1.37
Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg (1996) 1.35
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer (2005) 1.34
Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res (1997) 1.34
Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity. Antimicrob Agents Chemother (1979) 1.33
Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol (1991) 1.33
Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer (2009) 1.32
Acyclovir and suppression of frequently recurring herpetic whitlow. Ann Intern Med (1985) 1.29
Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol (1998) 1.29
Hypoprothrombinemia and platelet dysfunction caused by cephalosporin and oxalactam antibiotics. J Antimicrob Chemother (1983) 1.28
A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer (1996) 1.27
Disposition of intravenous radioactive acyclovir. Clin Pharmacol Ther (1981) 1.27
Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res (1997) 1.27
Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg (1994) 1.25
Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg (2000) 1.24
Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am J Med (1987) 1.22
Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med Virol (1993) 1.22
Kinetics in interactions between antibodies and haptens. Biochemistry (1975) 1.21
Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol (1990) 1.20
Drug-grapefruit juice interactions. Mayo Clin Proc (2000) 1.19
Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin Cancer Res (1999) 1.18
Clinical pharmacokinetics of acyclovir. Clin Pharmacokinet (1983) 1.16
Mechanism of the inhibition of the gamma-carboxylation of glutamic acid by N-methylthiotetrazole-containing antibiotics. Proc Natl Acad Sci U S A (1984) 1.16
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene (1999) 1.15
Homophilic adhesion of human CEACAM1 involves N-terminal domain interactions: structural analysis of the binding site. Blood (2001) 1.15
Aminoglycoside inhibition of a renal phosphatidylinositol phospholipase C. J Pharmacol Exp Ther (1982) 1.14
Monoclonal antibodies that recognize lacto-N-fucopentaose III (CD15) react with the adhesion-promoting glycoprotein family (LFA-1/HMac-1/gp 150,95) and CR1 on human neutrophils. J Immunol (1987) 1.13
Antiviral therapy for cytomegalovirus retinitis in AIDS with dihydroxy propoxymethyl guanine. Am J Ophthalmol (1986) 1.13
Determination of antibody-hapten association kinetics: a simplified experimental approach. J Immunol (1975) 1.13
Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer (1998) 1.13
Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut (2001) 1.12
Comparison of granule proteins from human polymorphonuclear leukocytes which are bactericidal toward Pseudomonas aeruginosa. Infect Immun (1991) 1.11
Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut (2001) 1.11
Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther (1987) 1.10
Significance of peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreatic head. Surgery (1995) 1.09
Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob Agents Chemother (1982) 1.07
Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans. Antimicrob Agents Chemother (1982) 1.07
Production of hypoprothrombinemia by moxalactam and 1-methyl-5-thiotetrazole in rats. Antimicrob Agents Chemother (1984) 1.07
Unknown primary tumors metastatic to liver. J Clin Oncol (1998) 1.06
Concomitant herpes simplex virus type 1 and cytomegalovirus ventriculoencephalitis in acquired immunodeficiency syndrome. Arch Neurol (1987) 1.06
Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol (1994) 1.05
In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res (2001) 1.05
Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer. Invest New Drugs (1996) 1.05
Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res (2000) 1.05
Cooperation between transcription factor AP-1 and NF-kappaB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia. J Interferon Cytokine Res (1999) 1.04
Utility of a "swish and spit" technique for the collection of buccal cells for TAP haplotype determination. Mayo Clin Proc (1995) 1.04
Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology (2012) 1.04
Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol (2001) 1.03
Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. J Gastrointest Surg (2000) 1.02
Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections. A randomized, double-blind trial. Ann Intern Med (1984) 1.02
Measles antibody seroprevalence rates among immunized Inuit, Innu and Caucasian subjects. Vaccine (1999) 1.02
DNA adducts in human pancreatic tissues and their potential role in carcinogenesis. Cancer Res (1998) 1.01
An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology (1995) 1.01
bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res (1996) 1.01
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. Ann Oncol (2002) 0.99
Activation of human phagocytes through carbohydrate antigens (CD15, sialyl-CD15, CDw17, and CDw65). J Immunol (1992) 0.99
Double-blind comparison of cefamandole and penicillin in pneumococcal pneumonia. Antimicrob Agents Chemother (1978) 0.99
Netilmicin and gentamicin multidose kinetics in normal subjects. Clin Pharmacol Ther (1983) 0.99
Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. J Clin Oncol (2000) 0.98
Nonlethal adherence to human neutrophils mediated by Dr antigen-specific adhesins of Escherichia coli. Infect Immun (1995) 0.98
Induction of ductal and stromal hyperplasia by basic fibroblast growth factor produced by human pancreatic carcinoma. Int J Oncol (2001) 0.98